Gene,Variant,Cancer Type,Drug
ABL1,T315I,B-Lymphoblastic Leukemia/Lymphoma,Ponatinib
ABL1,T315I,Chronic Myelogenous Leukemia,Asciminib
ABL1,T315I,Chronic Myelogenous Leukemia,Ponatinib
AKT1,E17K,Breast Cancer,Capivasertib + Fulvestrant
BRAF,V600,Erdheim-Chester Disease,Vemurafenib
BRAF,V600,"Low-Grade Glioma, NOS",Tovorafenib
BRAF,V600,Melanoma,Vemurafenib + Atezolizumab + Cobimetinib
BRAF,V600E,All Solid Tumors (excluding Colorectal Cancer),Dabrafenib + Trametinib
BRAF,V600E,Anaplastic Thyroid Cancer,Dabrafenib + Trametinib
BRAF,V600E,"Biliary Tract Cancer, NOS",Dabrafenib + Trametinib
BRAF,V600E,Colorectal Cancer,Encorafenib + Cetuximab
BRAF,V600E,"Low-Grade Glioma, NOS",Dabrafenib + Trametinib
BRAF,V600E,Melanoma,Dabrafenib
BRAF,V600E,Melanoma,Vemurafenib
BRAF,V600E,Non-Small Cell Lung Cancer,Dabrafenib + Trametinib
BRAF,V600E,Non-Small Cell Lung Cancer,Encorafenib + Binimetinib
BRAF,"V600E, V600K",Melanoma,Dabrafenib + Trametinib
BRAF,"V600E, V600K",Melanoma,Encorafenib + Binimetinib
BRAF,"V600E, V600K",Melanoma,Trametinib
BRAF,"V600E, V600K",Melanoma,Vemurafenib + Cobimetinib
EGFR,"Exon 19 in-frame deletions (729_761del), L858R",Non-Small Cell Lung Cancer,Afatinib
EGFR,"Exon 19 in-frame deletions (729_761del), L858R",Non-Small Cell Lung Cancer,Amivantamab + Chemotherapy
EGFR,"Exon 19 in-frame deletions (729_761del), L858R",Non-Small Cell Lung Cancer,Amivantamab + Lazertinib
EGFR,"Exon 19 in-frame deletions (729_761del), L858R",Non-Small Cell Lung Cancer,Dacomitinib
EGFR,"Exon 19 in-frame deletions (729_761del), L858R",Non-Small Cell Lung Cancer,Erlotinib
EGFR,"Exon 19 in-frame deletions (729_761del), L858R",Non-Small Cell Lung Cancer,Erlotinib + Ramucirumab
EGFR,"Exon 19 in-frame deletions (729_761del), L858R",Non-Small Cell Lung Cancer,Gefitinib
EGFR,"Exon 19 in-frame deletions (729_761del), L858R",Non-Small Cell Lung Cancer,Osimertinib
EGFR,"Exon 19 in-frame deletions (729_761del), L858R",Non-Small Cell Lung Cancer,Osimertinib + Chemotherapy
EGFR,T790M,Non-Small Cell Lung Cancer,Osimertinib
EGFR,S768I,Non-Small Cell Lung Cancer,Afatinib
EGFR,L861Q,Non-Small Cell Lung Cancer,Afatinib
EGFR,G719,Non-Small Cell Lung Cancer,Afatinib
EGFR,Exon 20 in-frame insertions (762_823ins),Non-Small Cell Lung Cancer,Amivantamab + Chemotherapy
EGFR,Exon 20 in-frame insertions (762_823ins),Non-Small Cell Lung Cancer,Amivantamab
FGFR3,"G370C, R248C, S249C, Y373C",Bladder Cancer,Erdafitinib
ESR1,"D538, E380, L469V, L536, S463P, Y537,
V422del",Breast Cancer,Elacestrant
FLT3,"D835, I836, Internal tandem duplication (572_630ins)",Acute Myeloid Leukemia,Gilteritinib
IDH1,"R132C, R132G, R132H, R132L, R132S",Acute Myeloid Leukemia,Olutasidenib
IDH1,"R132C, R132G, R132H, R132L, R132S","Intrahepatic Cholangiocarcinoma, Cholangiocarcinoma",Ivosidenib
IDH1,"R132C, R132G, R132H, R132L, R132S","Oligodendroglioma, Astrocytoma",Vorasidenib
IDH2,R140G and 8 other alterations,Acute Myeloid Leukemia,Enasidenib
IDH2,"R172G, R172K, R172M, R172S, R172W","Oligodendroglioma, Astrocytoma",Vorasidenib
EGFR,Exon 19 in-frame insertions (729_761ins),Non-Small Cell Lung Cancer,Gefitinib
EGFR,G724S,Non-Small Cell Lung Cancer,Afatinib
EGFR,G719,Non-Small Cell Lung Cancer,Amivantamab + Lazertinib
EGFR,Exon 20 in-frame insertions (762_823ins),Non-Small Cell Lung Cancer,Poziotinib
EGFR,Exon 20 in-frame insertions (762_823ins),Non-Small Cell Lung Cancer,CLN-081
EGFR,Exon 19 in-frame insertions (729_761ins),Non-Small Cell Lung Cancer,Erlotinib
EGFR,Exon 19 in-frame deletions (729_761del) and 5 other alterations,Non-Small Cell Lung Cancer,Patritumab Deruxtecan
EGFR,E709_T710delinsD,Non-Small Cell Lung Cancer,Afatinib
BRAF,V600,Histiocytosis,Vemurafenib
BRAF,V600,Histiocytosis,Dabrafenib
BRAF,L597,Melanoma,Trametinib
BRAF,K601,Melanoma,Trametinib
KIT,D816,Mastocytosis,Avapritinib
IDH1,"R132C, R132G, R132H, R132L, R132S",Myelodysplastic Syndromes,Ivosidenib
IDH1,"R132C, R132G, R132H, R132L, R132S",Acute Myeloid Leukemia,Ivosidenib
FLT3,Internal tandem duplication (572_630ins),Acute Myeloid Leukemia,Quizartinib
FLT3,"D835, I836, Internal tandem duplication (572_630ins)",Acute Myeloid Leukemia,Midostaurin + High Dose Chemotherapy
EZH2,"A682G,  A692V, Y646C,  Y646F,  Y646H, Y646N, Y646S",Follicular Lymphoma,Tazemetostat
KRAS,G12C,Colorectal Cancer,Adagrasib + Cetuximab
KRAS,G12C,Colorectal Cancer,Sotorasib + Panitumumab
KRAS,G12C,Non-Small Cell Lung Cancer,Adagrasib
KRAS,G12C,Non-Small Cell Lung Cancer,Sotorasib
MET,"D1010, Exon 14 Deletion, Exon 14 in-frame deletions (963_1010del), Exon 14 splice mutations (963_1010splice)",Non-Small Cell Lung Cancer,Capmatinib
MET,"D1010, Exon 14 Deletion, Exon 14 in-frame deletions (963_1010del), Exon 14 splice mutations (963_1010splice)",Non-Small Cell Lung Cancer,Tepotinib
PDGFRA,"Exon 18 in-frame deletions (814_852del), Exon 18 in-frame insertions (814_852ins), Exon 18 missense mutations (814_852mis)",Gastrointestinal Stromal Tumor,Avapritinib
PIK3CA,C420R and 10 other alterations,Breast Cancer,Alpelisib + Fulvestrant
PIK3CA,C420R and 10 other alterations,Breast Cancer,Capivasertib + Fulvestrant
PIK3CA,E545Q and 7 other alterations,Breast Cancer,Capivasertib + Fulvestrant
ABL1,E255K and 12 other alterations,B-Lymphoblastic Leukemia/Lymphoma,Imatinib
ABL1,E255K and 12 other alterations,Chronic Myelogenous Leukemia,Imatinib
ABL1,E255K and 6 other alterations,B-Lymphoblastic Leukemia/Lymphoma,Nilotinib
ABL1,E255K and 6 other alterations,Chronic Myelogenous Leukemia,Nilotinib
ABL1,F317C and 5 other alterations,B-Lymphoblastic Leukemia/Lymphoma,Dasatinib
ABL1,F317C and 5 other alterations,Chronic Myelogenous Leukemia,Dasatinib
ABL1,"F317L, G250E, V299L",B-Lymphoblastic Leukemia/Lymphoma,Bosutinib
ABL1,"F317L, G250E, V299L",Chronic Myelogenous Leukemia,Bosutinib
ABL1,T315I,B-Lymphoblastic Leukemia/Lymphoma,Bosutinib
ABL1,T315I,B-Lymphoblastic Leukemia/Lymphoma,Dasatinib
ABL1,T315I,B-Lymphoblastic Leukemia/Lymphoma,Imatinib
ABL1,T315I,B-Lymphoblastic Leukemia/Lymphoma,Nilotinib
ABL1,T315I,Chronic Myelogenous Leukemia,Bosutinib
ABL1,T315I,Chronic Myelogenous Leukemia,Dasatinib
ABL1,T315I,Chronic Myelogenous Leukemia,Imatinib
ABL1,T315I,Chronic Myelogenous Leukemia,Nilotinib
BTK,C481S,Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma,Ibrutinib
EGFR,Exon 20 in-frame insertions,Non-Small Cell Lung Cancer,Afatinib
EGFR,Exon 20 in-frame insertions,Non-Small Cell Lung Cancer,Erlotinib
EGFR,Exon 20 in-frame insertions,Non-Small Cell Lung Cancer,Gefitinib
EGFR,T790M,Non-Small Cell Lung Cancer,Afatinib
EGFR,T790M,Non-Small Cell Lung Cancer,Erlotinib
EGFR,T790M,Non-Small Cell Lung Cancer,Gefitinib
NTRK1,G595R,All Solid Tumors,Larotrectinib
NTRK3,F617L,All Solid Tumors,Larotrectinib
NTRK3,G623R,All Solid Tumors,Larotrectinib
NTRK3,G696A,All Solid Tumors,Larotrectinib
PDGFRA,D842V,Gastrointestinal Stromal Tumor,Imatinib
ABL1,E255K and 9 other alterations,B-Lymphoblastic Leukemia/Lymphoma,Bosutinib
ABL1,E255K and 9 other alterations,Chronic Myelogenous Leukemia,Bosutinib
ABL1,E255K and 5 other alterations,B-Lymphoblastic Leukemia/Lymphoma,Dasatinib
ABL1,E255K and 5 other alterations,Chronic Myelogenous Leukemia,Dasatinib
ABL1,F317C and 5 other alterations,B-Lymphoblastic Leukemia/Lymphoma,Nilotinib
ABL1,F317C and 5 other alterations,Chronic Myelogenous Leukemia,Nilotinib
ALK,G1202R,Non-Small Cell Lung Cancer,Lorlatinib
ALK,L1196M,Non-Small Cell Lung Cancer,Lorlatinib
BRAF,V600,Langerhans Cell Histiocytosis,Dabrafenib
BRAF,V600,Langerhans Cell Histiocytosis,Vemurafenib
BRAF,V600 (excluding V600E and V600K),Melanoma,Dabrafenib + Trametinib
BRAF,V600 (excluding V600E and V600K),Melanoma,Encorafenib + Binimetinib
BRAF,V600 (excluding V600E and V600K),Melanoma,Vemurafenib + Cobimetinib
BRAF,V600E,Colorectal Cancer,Encorafenib + Panitumumab
BRAF,V600E,"Diffuse Glioma (excluding Diffuse Intrinsic Pontine Glioma, Diffuse Astrocytoma, Anaplastic Oligodendroglioma, Oligodendroglioma, Oligoastrocytoma, Astrocytoma)",Vemurafenib + Cobimetinib
BRAF,V600E,Encapsulated Glioma,Vemurafenib + Cobimetinib
BRAF,V600E,Hairy Cell Leukemia,Vemurafenib
BRAF,V600E,Pilocytic Astrocytoma,Selumetinib
BRAF,V600E,"Pleomorphic Xanthoastrocytoma, Pilocytic Astrocytoma, Ganglioglioma",Vemurafenib + Cobimetinib
EGFR,A763_Y764insFQEA,Non-Small Cell Lung Cancer,Erlotinib
EGFR,G719,Non-Small Cell Lung Cancer,Amivantamab + Chemotherapy
EGFR,G719,Non-Small Cell Lung Cancer,Dacomitinib
EGFR,G719,Non-Small Cell Lung Cancer,Erlotinib
EGFR,G719,Non-Small Cell Lung Cancer,Gefitinib
EGFR,G719,Non-Small Cell Lung Cancer,Osimertinib
EGFR,L861Q,Non-Small Cell Lung Cancer,Amivantamab + Chemotherapy
EGFR,L861Q,Non-Small Cell Lung Cancer,Dacomitinib
EGFR,L861Q,Non-Small Cell Lung Cancer,Erlotinib
EGFR,L861Q,Non-Small Cell Lung Cancer,Gefitinib
EGFR,L861Q,Non-Small Cell Lung Cancer,Osimertinib
EGFR,S768I,Non-Small Cell Lung Cancer,Amivantamab + Chemotherapy
EGFR,S768I,Non-Small Cell Lung Cancer,Dacomitinib
EGFR,S768I,Non-Small Cell Lung Cancer,Erlotinib
EGFR,S768I,Non-Small Cell Lung Cancer,Gefitinib
EGFR,S768I,Non-Small Cell Lung Cancer,Osimertinib
ESR1,V422del,Breast Cancer,Elacestrant
KIT,A829P and 5 other alterations,Gastrointestinal Stromal Tumor,Sorafenib
KIT,D579del and 12 other alterations,Melanoma,Imatinib
KRAS,G12C,Ampullary Cancer,Adagrasib
KRAS,G12C,Ampullary Cancer,Sotorasib
KRAS,G12C,Colorectal Cancer,Adagrasib + Panitumumab
KRAS,G12C,Colorectal Cancer,Sotorasib + Cetuximab
KRAS,G12C,Hepatobiliary Cancer,Adagrasib
KRAS,G12C,Pancreatic Adenocarcinoma,Adagrasib
KRAS,G12C,Pancreatic Adenocarcinoma,Sotorasib
KRAS,G12C,Small Bowel Cancer,Adagrasib
KRAS,G12C,Small Bowel Cancer,Sotorasib
MET,"D1010, Exon 14 Deletion, Exon 14 in-frame deletions (963_1010del), Exon 14 splice mutations (963_1010splice)",Non-Small Cell Lung Cancer,Crizotinib
PDGFRA,D842V,Gastrointestinal Stromal Tumor,Dasatinib
POLD1,"D402N, E318K, L474P, S478N",Colorectal Cancer,Dostarlimab
POLD1,"D402N, E318K, L474P, S478N",Colorectal Cancer,Ipilimumab + Nivolumab
POLD1,"D402N, E318K, L474P, S478N",Colorectal Cancer,Nivolumab
POLD1,"D402N, E318K, L474P, S478N",Colorectal Cancer,Pembrolizumab
POLD1,"D402N, E318K, L474P, S478N",Small Bowel Cancer,Dostarlimab
POLD1,"D402N, E318K, L474P, S478N",Small Bowel Cancer,Ipilimumab + Nivolumab
POLD1,"D402N, E318K, L474P, S478N",Small Bowel Cancer,Nivolumab
POLD1,"D402N, E318K, L474P, S478N",Small Bowel Cancer,Pembrolizumab
POLE,A288V and 36 other alterations,Colorectal Cancer,Dostarlimab
POLE,A288V and 36 other alterations,Colorectal Cancer,Ipilimumab + Nivolumab
POLE,A288V and 36 other alterations,Colorectal Cancer,Nivolumab
POLE,A288V and 36 other alterations,Colorectal Cancer,Pembrolizumab
POLE,A288V and 36 other alterations,Small Bowel Cancer,Dostarlimab
POLE,A288V and 36 other alterations,Small Bowel Cancer,Ipilimumab + Nivolumab
POLE,A288V and 36 other alterations,Small Bowel Cancer,Nivolumab
POLE,A288V and 36 other alterations,Small Bowel Cancer,Pembrolizumab
AKT1,E17K,"Ovarian Cancer, Endometrial Cancer",Capivasertib
ALK,F1174C,Neuroblastoma,Lorlatinib
ALK,F1174L,Neuroblastoma,Lorlatinib
ALK,F1245V,Neuroblastoma,Lorlatinib
ALK,F1245Y,Neuroblastoma,Lorlatinib
ALK,G1202R,Non-Small Cell Lung Cancer,NVL-655
ALK,R1275L,Neuroblastoma,Lorlatinib
ALK,R1275Q,Neuroblastoma,Lorlatinib
EGFR,L861Q,Non-Small Cell Lung Cancer,Amivantamab + Lazertinib
EGFR,S768I,Non-Small Cell Lung Cancer,Amivantamab + Lazertinib
FLT3,Internal tandem duplication (572_630ins),Acute Myeloid Leukemia,Crenolanib
FLT3,Internal tandem duplication (572_630ins),Acute Myeloid Leukemia,Sorafenib
IDH1,R132,Glioma,Ivosidenib
KRAS,"G12A, G12D, G12R, G12S, G12V",Non-Small Cell Lung Cancer,RMC-6236
KRAS,"G12A, G12D, G12R, G12S, G12V",Pancreatic Adenocarcinoma,RMC-6236
KRAS,G12C,"Tubular Adenoma of the Colon, Esophagogastric Cancer, Anal Cancer, Gastrointestinal Neuroendocrine Tumors of the Esophagus/Stomach",Adagrasib
KRAS,G12D,Non-Small Cell Lung Cancer,ASP3082
KRAS,G12D,Pancreatic Adenocarcinoma,ASP3082
MET,F1200I,Non-Small Cell Lung Cancer,Elzovantinib
MET,H1094Y,Non-Small Cell Lung Cancer,Elzovantinib
MET,Y1003,Non-Small Cell Lung Cancer,Capmatinib
MET,Y1003,Non-Small Cell Lung Cancer,Crizotinib
MET,Y1003,Non-Small Cell Lung Cancer,Tepotinib
MTOR,"E2014K, E2419K",Bladder Cancer,Everolimus
MTOR,"L2209V, L2427Q",Renal Cell Carcinoma,Temsirolimus
MTOR,Q2223K,Renal Cell Carcinoma,Everolimus
NTRK1,G595R,All Solid Tumors,Selitrectinib
NTRK3,G623R,All Solid Tumors,Selitrectinib
ROS1,G2032R,Non-Small Cell Lung Cancer,Taletrectinib
ROS1,L2086F,Non-Small Cell Lung Cancer,Cabozantinib
TP53,Y220C,All Solid Tumors,Rezatapopt
BRAF,"G464, G469A, G469R, G469V",All Solid Tumors,Plixorafenib
BRAF,K601,All Solid Tumors,Plixorafenib
BRAF,L597,All Solid Tumors,Plixorafenib
EGFR,"A289V, R108K, T263P",Glioma,Lapatinib
EGFR,A763_Y764insFQEA,Non-Small Cell Lung Cancer,Afatinib
EGFR,D761Y,Non-Small Cell Lung Cancer,Osimertinib
EGFR,Exon 19 in-frame insertions (729_761ins),Non-Small Cell Lung Cancer,Afatinib
EGFR,L747P,Non-Small Cell Lung Cancer,Afatinib
KIT,A829P and 5 other alterations,Gastrointestinal Stromal Tumor,Nilotinib
KIT,A829P and 5 other alterations,Gastrointestinal Stromal Tumor,Pazopanib
KRAS,"G12A, G12D, G12R, G12S, G12V",All Solid Tumors,RMC-6236
KRAS,G12D,All Solid Tumors,ASP3082
KRAS,G12D,All Solid Tumors,MRTX-1133
MET,"H1106D, M1250T, N1100S, R1170Q, V1092I",Non-Small Cell Lung Cancer,Capmatinib
MET,"H1106D, M1250T, N1100S, R1170Q, V1092I",Non-Small Cell Lung Cancer,Elzovantinib
MET,"H1106D, M1250T, N1100S, R1170Q, V1092I",Non-Small Cell Lung Cancer,Tepotinib
NTRK1,G595R,All Solid Tumors,Zurletrectinib
NTRK3,G623R,All Solid Tumors,Zurletrectinib
ALK,C1156Y,Non-Small Cell Lung Cancer,Crizotinib
ALK,G1202R,Non-Small Cell Lung Cancer,Alectinib
ALK,G1202R,Non-Small Cell Lung Cancer,Brigatinib
ALK,G1202R,Non-Small Cell Lung Cancer,Ceritinib
ALK,G1202R,Non-Small Cell Lung Cancer,Crizotinib
ALK,G1269A,Non-Small Cell Lung Cancer,Crizotinib
ALK,I1171N,Non-Small Cell Lung Cancer,Alectinib
ALK,L1196M,Non-Small Cell Lung Cancer,Crizotinib
BTK,C481F,Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma,Ibrutinib
BTK,C481R,Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma,Ibrutinib
BTK,C481Y,Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma,Ibrutinib
BTK,T316A,Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma,Ibrutinib
BTK,T474I,Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma,Ibrutinib
BTK,T474S,Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma,Ibrutinib
EGFR,C797G,Non-Small Cell Lung Cancer,Osimertinib
EGFR,C797S,Non-Small Cell Lung Cancer,Osimertinib
EGFR,D761Y,Non-Small Cell Lung Cancer,Gefitinib
EGFR,G465E,Colorectal Cancer,Cetuximab
EGFR,G465E,Colorectal Cancer,Panitumumab
EGFR,G465R,Colorectal Cancer,Cetuximab
EGFR,G465R,Colorectal Cancer,Panitumumab
EGFR,G724S,Non-Small Cell Lung Cancer,Osimertinib
EGFR,L718Q,Non-Small Cell Lung Cancer,Osimertinib
EGFR,L718V,Non-Small Cell Lung Cancer,Osimertinib
EGFR,L792F,Non-Small Cell Lung Cancer,Osimertinib
EGFR,L792H,Non-Small Cell Lung Cancer,Osimertinib
EGFR,S464L,Colorectal Cancer,Cetuximab
EGFR,S464L,Colorectal Cancer,Panitumumab
EGFR,S492R,Colorectal Cancer,Cetuximab
EGFR,S492R,Colorectal Cancer,Panitumumab
EGFR,V441D,Colorectal Cancer,Cetuximab
EGFR,V441D,Colorectal Cancer,Panitumumab
EGFR,V441G,Colorectal Cancer,Cetuximab
EGFR,V441G,Colorectal Cancer,Panitumumab
KIT,A829P,Gastrointestinal Stromal Tumor,Imatinib
KIT,A829P,Gastrointestinal Stromal Tumor,Sunitinib
KIT,C809G,Gastrointestinal Stromal Tumor,Imatinib
KIT,C809G,Gastrointestinal Stromal Tumor,Sunitinib
KIT,D816,Gastrointestinal Stromal Tumor,Imatinib
KIT,D816,Gastrointestinal Stromal Tumor,Sunitinib
KIT,D820,Gastrointestinal Stromal Tumor,Imatinib
KIT,D820,Gastrointestinal Stromal Tumor,Sunitinib
KIT,N822,Gastrointestinal Stromal Tumor,Imatinib
KIT,N822,Gastrointestinal Stromal Tumor,Sunitinib
KIT,T670I,Gastrointestinal Stromal Tumor,Imatinib
KIT,V654A,Gastrointestinal Stromal Tumor,Imatinib
KIT,Y823D,Gastrointestinal Stromal Tumor,Imatinib
KIT,Y823D,Gastrointestinal Stromal Tumor,Sunitinib
MET,D1228N,Non-Small Cell Lung Cancer,Cabozantinib
MET,D1228N,Non-Small Cell Lung Cancer,Capmatinib
MET,D1228N,Non-Small Cell Lung Cancer,Crizotinib
MET,Y1230H,Non-Small Cell Lung Cancer,Capmatinib
MET,Y1230H,Non-Small Cell Lung Cancer,Crizotinib
NTRK1,G595R,All Solid Tumors,Entrectinib
ROS1,G2032R,Non-Small Cell Lung Cancer,Crizotinib
ROS1,G2032R,Non-Small Cell Lung Cancer,Lorlatinib
ROS1,L2086F,Non-Small Cell Lung Cancer,Lorlatinib
ROS1,L2086F,Non-Small Cell Lung Cancer,Repotrectinib
